Paeoniflorin Ameliorates Colonic Fibrosis In Rats With Post-Infectious Irritable Bowel Syndrome By Inhibiting The Leptin/Leprb Pathway
Abstract Post-infectious irritable bowel syndrome (PI-IBS) is a highly prevalent gastrointestinal disorder associated with immune dysregulation and depression- and anxiety-like behaviors. The active ingredient of Paeoniae Radix called paeoniflorin (PF) was previously found to prevent the symptoms of PI-IBS. However, there is limited information on the effects of PF on the intestinal function and depression- and anxiety-like symptoms in PI-IBS animal models. Here, we aimed to determine the effects of PF treatment on the symptoms of PI-IBS in a rat model. After the experimental period, the PI‑IBS rats presented decreased body weight and increased fecal water content, which coincided with the elevated leptin levels and heightened depression- and anxiety-like behaviors (e.g., low sucrose intake, less frequency in the center areas during open field test). However, the PF treatment ameliorated these observed symptoms. Furthermore, PF not only inhibited leptin/LepRb expression, but also reduced the PI3K/AKT phosphorylation and brain-derived neurotrophic factor (BDNF) expression in PI-IBS rats. Notably, co-treatment with leptin (10 mg/kg) reduced the effects of PF (20 mg/kg) on colonic fibrosis, leptin/LepRb expression, and PI3K/AKT activation. Therefore, our findings suggest that leptin is targeted by PF via the leptin/LepRb pathway, consequently ameliorating the symptoms of PI-IBS. Our study also contribute novel insights for elucidating the pharmacological action of PF on gastrointestinal disorders and may be used for the clinical treatment of PI-IBS in the future..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ResearchSquare.com - (2022) vom: 14. Apr. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cao, Di [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.21203/rs.3.rs-1269042/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA035331550 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA035331550 | ||
| 003 | DE-627 | ||
| 005 | 20230429200319.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-1269042/v1 |2 doi | |
| 035 | |a (DE-627)XRA035331550 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-1269042/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Cao, Di |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Paeoniflorin Ameliorates Colonic Fibrosis In Rats With Post-Infectious Irritable Bowel Syndrome By Inhibiting The Leptin/Leprb Pathway |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Post-infectious irritable bowel syndrome (PI-IBS) is a highly prevalent gastrointestinal disorder associated with immune dysregulation and depression- and anxiety-like behaviors. The active ingredient of Paeoniae Radix called paeoniflorin (PF) was previously found to prevent the symptoms of PI-IBS. However, there is limited information on the effects of PF on the intestinal function and depression- and anxiety-like symptoms in PI-IBS animal models. Here, we aimed to determine the effects of PF treatment on the symptoms of PI-IBS in a rat model. After the experimental period, the PI‑IBS rats presented decreased body weight and increased fecal water content, which coincided with the elevated leptin levels and heightened depression- and anxiety-like behaviors (e.g., low sucrose intake, less frequency in the center areas during open field test). However, the PF treatment ameliorated these observed symptoms. Furthermore, PF not only inhibited leptin/LepRb expression, but also reduced the PI3K/AKT phosphorylation and brain-derived neurotrophic factor (BDNF) expression in PI-IBS rats. Notably, co-treatment with leptin (10 mg/kg) reduced the effects of PF (20 mg/kg) on colonic fibrosis, leptin/LepRb expression, and PI3K/AKT activation. Therefore, our findings suggest that leptin is targeted by PF via the leptin/LepRb pathway, consequently ameliorating the symptoms of PI-IBS. Our study also contribute novel insights for elucidating the pharmacological action of PF on gastrointestinal disorders and may be used for the clinical treatment of PI-IBS in the future. | ||
| 700 | 1 | |a Wu, Yaning |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Kunli |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Yijun |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Yaqing |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Qixiang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Huihui |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xiaoping |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Yongqiu |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Fengyun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2022) vom: 14. Apr. |
| 773 | 1 | 8 | |g year:2022 |g day:14 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-1269042/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 14 |c 04 | ||
| 953 | |2 045F |a 570 | ||